Anti-MDA5 antibody dermatomyositis-associated rapidly progressive interstitial lung disease patient complicated with mixed connective tissue disease: A case report

被引:0
|
作者
Wu, Hua-Man [1 ]
Liu, Xian-hong [1 ]
Deng, Li-Ping [1 ]
Lv, Feng-Yuan [1 ]
Zhang, Mei-Xia [1 ]
Luo, Jun-Ping [1 ]
Tian, Mao-Liang [1 ]
Deng, Zhi-Ping [1 ,2 ]
机构
[1] Zigong First Peoples Hosp, Dept Resp & Crit Care Med, Zigong, Sichuan, Peoples R China
[2] Zigong First Peoples Hosp, Dept Resp & Crit Care Med, 42 Shangyihao Rd, Zigong 643000, Peoples R China
关键词
anti-MDA5 antibody dermatomyositis; anti-Ro52; antibody; mixed connective tissue disease; prognosis; rapidly progressive interstitial lung disease; AUTOANTIBODIES; MORTALITY;
D O I
10.1111/1756-185X.14575
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anti-MDA5 antibody dermatomyositis (DM) is a special type of myositis, which can potentially cause rapidly progressive interstitial lung disease (RP-ILD). Mixed connective tissue disease (MCTD) is a complex disease with different characteristics of autoimmune connective tissue disease, associated with ILD. Both are rare diseases, and few patients with both diseases have been reported. A 71-year-old woman complained of palpitations, with a 2 months history of rash around her hands, extensor surface of right elbow, and the nape of her neck. Subsequently, the patient had acute exacerbation of dyspnea and tachypnea. Anti-Ro52, U1 RNP and MDA5 antibodies were positive; the presenting evidence was suggestive of anti-MDA5(+)DM-RP-ILD complicated with MCTD. Our patient deteriorated rapidly and had a fatal outcome, despite "triple therapy" for RP-ILD. This case illustrates that patients with coexisting anti-MDA5(+)DM and MCTD have the former's typical clinical manifestations, and may develop ILD quickly rather than slowly as in MCTD, especially with the coexistence of anti-Ro52 antibodies.
引用
收藏
页码:1137 / 1142
页数:6
相关论文
共 50 条
  • [31] Rituximab in the treatment of anti-MDA5 dermatomyositis-associated interstitial lung disease: a case-based literature review
    Nascimento, J.
    Tenazinha, C.
    Campanilho-Marques, R.
    Cordeiro, I
    Salgado, S.
    ARP RHEUMATOLOGY, 2022, 1 (02): : 168 - 173
  • [32] Rapidly progressive interstitial lung fibrosis in a patient with amyopathic dermatomyositis and anti-MDA5 antibodies
    Gorka, Jacek
    Szczeklik, Wojciech
    Wludarczyk, Anna
    Loboda, Piotr
    Chmura, Lukasz
    Musial, Jacek
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2015, 125 (09): : 685 - 686
  • [33] Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease disguising as anti-synthetase syndrome
    Tanaka, Nao
    Terao, Chikashi
    Nakayama, Yoichi
    Sasai, Tsuneo
    Umezawa, Natsuka
    Yagyu, Yuriko
    Ito, Kanae
    Koike, Ryuji
    Nakashima, Ran
    Hatta, Kazuhiro
    Mizoguchi, Fumitaka
    RHEUMATOLOGY, 2021, 60 (03) : E104 - E106
  • [34] Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease
    Fujisawa, Tomoyuki
    Hozumi, Hironao
    Yasui, Hideki
    Suzuki, Yuzo
    Karayama, Masato
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Nakamura, Yutaro
    Inui, Naoki
    Suda, Takafumi
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (08) : 935 - 942
  • [35] Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
    Sakamoto, Noriho
    Ishimoto, Hiroshi
    Nakashima, Shota
    Yura, Hirokazu
    Miyamura, Takuto
    Okuno, Daisuke
    Hara, Atsuko
    Kitazaki, Takeshi
    Kakugawa, Tomoyuki
    Ishimatsu, Yuji
    Satoh, Minoru
    Mukae, Hiroshi
    INTERNAL MEDICINE, 2019, 58 (06) : 837 - 841
  • [36] Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis
    Ho So
    Victor Tak Lung Wong
    Virginia Weng Nga Lao
    Hin Ting Pang
    Ronald Man Lung Yip
    Clinical Rheumatology, 2018, 37 : 1983 - 1989
  • [37] Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis
    Takatani, Ayuko
    Koga, Tomohiro
    Fujita, Yuya
    Fukui, Shoichi
    Endo, Yushiro
    Shimizu, Toshimasa
    Kawakami, Atsushi
    CLINICAL IMMUNOLOGY, 2020, 215
  • [38] Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis
    So, Ho
    Wong, Victor Tak Lung
    Lao, Virginia Weng Nga
    Pang, Hin Ting
    Yip, Ronald Man Lung
    CLINICAL RHEUMATOLOGY, 2018, 37 (07) : 1983 - 1989
  • [39] A RARE CASE OF ANTI-MDA5 ANTIBODY-ASSOCIATED RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE WITHOUT CUTANEOUS MANIFESTATIONS
    Tavakolian, Kameron
    Douedi, Steven
    Pannu, Viraaj
    Miller, Brett
    Odak, Mihir
    Khan, Taimoor
    Salam, Noor
    CHEST, 2022, 162 (04) : 1183A - 1184A
  • [40] Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease
    A. Selva-O’Callaghan
    F. Romero-Bueno
    E. Trallero-Araguás
    A. Gil-Vila
    J. C. Ruiz-Rodríguez
    O. Sánchez-Pernaute
    I. Pinal-Fernández
    Current Treatment Options in Rheumatology, 2021, 7 : 319 - 333